Related Experiment Video
Updated: Oct 7, 2025
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
YK-4-279 Attenuates Progression of Pre-Existing Pigmented Lesions to Nodular Melanoma in a Mouse Model
Lee Huang1, Yougang Zhai1, Cristian D Fajardo1
1Department of Dermatology, Boston University, Boston, MA 02118, USA.
Abstract:
More options are needed for the effective treatment of melanoma. In a previous study, we discovered the small molecule drug YK-4-279 almost completely inhibited tumor progression in the Braf;Tyr-CreERT2;Pten transgenic mouse model. YK-4-279 had no effect on tumor initiation but blocked progression of invasive melanoma. Our current study was designed as a treatment model, where YK-4-279 was administered during pigmented lesion formation. The study design included the use of three groups: (1) a control group that received only DMSO without a drug (MOCK), (2) mice following our prior studies with YK-4-279 administered at the time of tumor induction (YK-4-279), and (3) mice treated during tumor initiation (YK-4-279 delay). While the MOCK mice had progression of tumors, both YK-4-279 and YK-4-279 delay groups had a significant block or delay of progression. The majority of mice in the YK-4-279 groups had a block of progression, while the YK-4-279 delay group had either a partial block (60% in male mice or 29% in females) or a delay in disease progression in females (28 days in controls to 50 days in YK-4-279 delay group). Here, we demonstrate that YK-4-279 has a significant impact on blocking or delaying tumor progression in a pre-clinical treatment model of melanoma.
Insights
The small molecule drug YK-4-279 effectively blocks or delays melanoma progression in a preclinical treatment model. This study shows YK-4-279 impacts tumor growth, offering new therapeutic options for melanoma.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Effective melanoma treatment options are limited.
- Previous research identified YK-4-279 as a potent inhibitor of melanoma tumor progression in a specific transgenic mouse model.
- YK-4-279 demonstrated an ability to block invasive melanoma progression without affecting tumor initiation.
Purpose of the Study:
- To evaluate YK-4-279 as a therapeutic agent in a melanoma treatment model.
- To assess the impact of YK-4-279 administration during the pigmented lesion formation stage.
- To compare the effects of YK-4-279 administered at tumor induction versus delayed administration during tumor initiation.
Main Methods:
- Utilized a Braf;Tyr-CreERT2;Pten transgenic mouse model for melanoma.
- Administered YK-4-279 or DMSO (MOCK control) in three groups: MOCK, YK-4-279 at tumor induction, and YK-4-279 delayed during tumor initiation.
- Monitored tumor progression and disease onset across all experimental groups.
Main Results:
- Mice in the MOCK group exhibited tumor progression.
- Both YK-4-279 and YK-4-279 delay groups showed a significant block or delay in melanoma progression.
- The YK-4-279 delay group demonstrated partial block (60% males, 29% females) or delayed progression (females: 28 to 50 days).
Conclusions:
- YK-4-279 significantly impacts melanoma tumor progression in a preclinical treatment setting.
- The drug demonstrates efficacy in blocking or delaying disease advancement, even when administered after initial tumor formation.
- These findings support YK-4-279 as a promising candidate for further investigation in melanoma therapy.
More Related Videos
12:37Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
Published on: September 7, 2013
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021